Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.

Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.

BACKGROUND: Current HIV-1 antiretroviral therapy (ART) greatly reduces virus replication but does not significantly affect the viral reservoir. Raltegravir, a recently introduced integrase inhibitor, could, at least theoretically, reduce residual viremia in patients on ART and affect the viral reser...

Full description

Bibliographic Details
Main Authors: Yu Ming Paul Lam, Kristin L McBride, Janaki Amin, Damien V Cordery, Anthony D Kelleher, David A Cooper, Kersten K Koelsch
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3291553?pdf=render

Similar Items

Similar Items